Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00603902 · ClinicalTrials.gov registry record · Phase 3
BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management
A Phase 3 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,008
- Enrollment target
NCT00603902: Completed Phase 3 study, sponsored by Eisai.
NCT00603902 is a Phase 3 study that has completed, run by Eisai. The registered enrollment target is 4,008 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (419% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00603902, a Phase 3 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,008 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients.
Primary Outcome
The percentage of patients with a reduction from baseline body weight of 5% or more after 52 weeks.
Interventions
- DRUG Matching Placebo
- DRUG Lorcaserin 10 mg once daily (QD)
- DRUG Lorcaserin 10 mg twice a day (BID)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,008 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
What the finished NCT00603902 record still lists
NCT00603902 is an interventional study that assigns participants to a tested intervention. Its 4,008 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (419% higher).
The record links to 0 conditions, and to 3 interventions - of which Matching Placebo is the first listed.
NCT00603902 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00603902 about?
NCT00603902 is a clinical study titled "BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management". The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients.
What is the current status of trial NCT00603902?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,008 participants. The study started on 2008-01. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00603902?
The interventions under investigation include: Matching Placebo (DRUG), Lorcaserin 10 mg once daily (QD) (DRUG), Lorcaserin 10 mg twice a day (BID) (DRUG).
Who is sponsoring clinical trial NCT00603902?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00603902's enrollment target sits among peer trials
4,008 61st of 2000 higher than 1,940 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00227253 · 4,000 participants
Chromosome 18 Clinical Research Center
- NCT00811148 · 4,000 participants
Florida Center for Brain Tumor Research
- NCT00897117 · 4,000 participants
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
- NCT00899301 · 4,000 participants
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia